☆ 4.7 Article

Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial

LIVER INTERNATIONAL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Gastroenterology & Hepatology

Interferon-based treatment of chronic hepatitis D

Lisa Sandmann et al.

Summary: Interferon-alfa has been the main treatment for hepatitis D virus (HDV) infection, but only a portion of patients benefit from it. Successful interferon treatment is associated with improved long-term clinical outcomes. Although alternative treatments are being developed, pegylated interferon-alfa still plays an important role. There is a need for better biomarkers to select patients who are likely to benefit from interferon-based treatments.

LIVER INTERNATIONAL (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Itemization difference of patient-reported outcome in patients with chronic liver disease

Ming-Chieh Lin et al.

Summary: The study investigated the impact of different etiologies on the health-related quality of life (HRQoL) of hepatitis patients in Asia. The findings revealed significant differences in physical health scores between CHC patients and CHB/NAFLD patients, as well as lower mental health scores in NAFLD patients compared to other groups.

PLOS ONE (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Bulevirtide with or without pegIFNa for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies

Pietro Lampertico et al.

Summary: Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, with increased risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Pegylated-interferon-a (pegIFNa) is the only off-label therapeutic option, but it has suboptimal response rates and poor tolerability. Among the new treatment strategies, the entry inhibitor bulevirtide (BLV) has gained conditional approval from the European Medicines Agency (EMA) and has shown efficacy and safety in clinical studies and real-world usage. BLV treatment could potentially improve the long-term prognosis of difficult-to-manage CHD patients.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R)

Valerie Ohlendorf et al.

Summary: DAA therapy is associated with an overall increase in HRQoL among HCV-infected patients, but roughly half of the patients fail to achieve a clinically important improvement. Patients with low HRQoL seem to benefit the most from modern therapeutic options.

JOURNAL OF VIRAL HEPATITIS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease

Stephan Urban et al.

Summary: Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with hepatitis D virus (HDV), leading to unfavorable outcomes such as liver cirrhosis, liver failure, and hepatocellular carcinoma. Recent advancements in understanding HDV virology and immunology have facilitated the development of specific antiviral drugs and potentially immunotherapeutic strategies. Novel treatment options, including the entry-inhibitor bulevirtide and prenylation inhibitor lonafarnib, show promise in making HDV a less difficult-to-treat virus.

GUT (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B

Maria Buti et al.

Summary: This study provides the first assessment of patient-reported outcomes in chronic hepatitis D (CHD) patients, showing significant impairment in some domains of health-related quality of life questionnaire compared to those with chronic hepatitis B (CHB). Further studies in larger cohorts with longer follow-up are needed to fully evaluate the impact of CHD on patient-reported quality of life.

JHEP REPORTS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies

Dulce Alfaiate et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes

Habiba Kamal et al.

HEPATOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis

Alexander J. Stockdale et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta

Dominique Roulot et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Infectious Diseases

Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

Heiner Wedemeyer et al.

LANCET INFECTIOUS DISEASES (2019)

添加到收藏夹

Article Immunology

Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease

Cihan Yurdaydin et al.

JOURNAL OF INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Antiviral Treatment and Liver- Related Complications in Hepatitis Delta

Anika Wranke et al.

HEPATOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis delta-associated mortality in HIV/HBV-coinfected patients

Charles Beguelin et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity

Katja Deterding et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Henry L. Y. Chan et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)

添加到收藏夹

Article Immunology

Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected Patients

Jose Vicente Fernandez-Montero et al.

CLINICAL INFECTIOUS DISEASES (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Development and evaluation of a baseline-event-anticipation score for hepatitis delta

B. Calle Serrano et al.

JOURNAL OF VIRAL HEPATITIS (2014)

添加到收藏夹

Article Health Care Sciences & Services

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

Vibeke Strand et al.

HEALTH AND QUALITY OF LIFE OUTCOMES (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Quality of life in patients with various liver diseases

H. L. Tillmann et al.

JOURNAL OF VIRAL HEPATITIS (2011)

添加到收藏夹

Article Medicine, General & Internal

Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta

Heiner Wedemeyer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease

G. Coteur et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)

添加到收藏夹

Article Psychology, Clinical

Pegylated Interferon and Ribavirin-Induced Depression in Chronic Hepatitis C: Role of Personality

Pere Castellvi et al.

JOURNAL OF CLINICAL PSYCHIATRY (2009)

添加到收藏夹

Article Gastroenterology & Hepatology

Host-rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection

B. Helbling et al.

GUT (2008)

添加到收藏夹

Article Gastroenterology & Hepatology

Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis

Herbert L. Bonkovsky et al.

JOURNAL OF HEPATOLOGY (2007)

添加到收藏夹

Article Pharmacology & Pharmacy

Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin

MR Kraus et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.